JOURNAL OF THE CZECH PHARMACEUTICAL SOCIETY AND THE SLOVAK PHARMACEUTICAL SOCIETY

Čes. slov. farm. 2024, 73(2):110-112 | DOI: 10.36290/csf.2024.013

Daprodustat: a new approach to the treatment of anemia in chronic kidney disease

Viktória Paulusová, Pavel Ryšánek, Martin Šíma, Ondřej Slanař
Farmakologický ústav, 1. lékařská fakulta, Univerzita Karlova a Všeobecná fakultní nemocnice v Praze

Daprodustat, also known under the trade name DUVROQ, is a small molecule developed by GlaxoSmithKline, which has become a promising drug in the field of anemia treatment in patients with chronic kidney disease. Daprodustat belongs to a group of drugs called hypoxia-inducible factor prolyl hydroxylase inhibitors. These drugs interfere with the regulation of erythropoietin, which is a key factor in the production of red blood cells. This drug was approved in Japan in June 2020 and clinical studies with it are ongoing in several countries around the world, where they focus on evaluating the effectiveness and safety in various populations of patients with chronic kidney disease.

Keywords: daprodustat, hypoxia-inducible factor prolyl hydroxylase inhibitors, chronic kidney disease.

Accepted: June 7, 2024; Published: June 14, 2024  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Paulusová V, Ryšánek P, Šíma M, Slanař O. Daprodustat: a new approach to the treatment of anemia in chronic kidney disease. Čes. slov. farm. 2024;73(2):110-112. doi: 10.36290/csf.2024.013.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Dhillon S. Daprodustat: First Approval. Drugs. 2020;80(14):1491-7. Go to original source... Go to PubMed...
    2. Kanai H, Nangaku M, Nagai R, Okuda N, Kurata K, Nagakubo T, et al. Efficacy and safety of daprodustat in Japanese peritoneal dialysis patients. Ther Apher Dial. 2021;25(6):979-87. Go to original source... Go to PubMed...
    3. Beninger P. Daprodustat. Clin Ther. 2023;45(5):480-1. Go to original source... Go to PubMed...
    4. Caltabiano S, Cizman B, Burns O, Mahar KM, Johnson BM, Ramanjineyulu B, et al. Effect of renal function and dialysis modality on daprodustat and predominant metabolite exposure. Clin Kidney J. 2019;12(5):693-701. Go to original source... Go to PubMed...
    5. Baker DE. Daprodustat. Hospital Pharmacy. 2023;58(6):530-43. Go to original source... Go to PubMed...
    6. Singh AK, Carroll K, McMurray JJV, Solomon S, Jha V, Johansen KL, et al. Daprodustat for the Treatment of Anemia in Patients Not Undergoing Dialysis. N Engl J Med. 2021;385(25):2313-24. Go to original source... Go to PubMed...
    7. Sanghani NS, Haase VH. Hypoxia-Inducible Factor Activators in Renal Anemia: Current Clinical Experience. Adv Chronic Kidney Dis. 2019;26(4):253-66. Go to original source... Go to PubMed...
    8. Ishii T, Tanaka T, Nangaku M. Profile of Daprodustat in the Treatment of Renal Anemia Due to Chronic Kidney Disease. Ther Clin Risk Manag. 2021;17:155-63. Go to original source... Go to PubMed...

    Return to the content


    Czech and Slovak Pharmacy

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.